Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5

Fig. 4

Correlation analysis of UCHL1 promoter CpG site methylation levels and gene expression in breast cancer tissues. (A) Comparison of UCHL1 expression in normal breast tissue (GTEx-B), TCGA breast cancer (TCGA-BRCA) subtypes, and adjacent cancer tissues (T adj.). (B) A heatmap (top) showing the correlation between UCHL1 expression and UCHL1 DNA methylation levels in corresponding tissues in TCGA-BRCA subtypes. The black box marks 7 methylation sites related to the promoter region. A bar chart (bottom) comparing UCHL1 DNA CpG site methylation levels in TCGA-BRCA subtypes. The black box marks 7 methylation sites related to the promoter region. (C) Correlation analysis of methylation levels of 7 methylation sites related to the promoter region and UCHL1 expression levels. (D) A UMP plot chart showing the single cells from breast cancer tissues, color-coded by UCHL1 expression (left) and their associated cell type cluster (right). (E) A scatter plot illustrates the expression of UCHL1 in various molecular subtypes of breast cancer and circulating tumor cells. The data is from a recent single-cell sequencing dataset [3], from: https://singlecell.broadinstitute.org/single_cell/study/SCP1039/a-single-cell-and-spatially-resolved-atlas-of-human-breast-cancers. (F) qRT-PCR was used to detect the expression of UCHL1 in MCF-7, BT-474, MDA-MB-468, and SUM149 cells. G-H.UCHL expression in MCF-7 and MDA-MB-468 cells after treatment with the methylation reagent 5-Aza-Dc at the mRNA (G) and protein (H) levels in MCF-7 and MDA-MB-468 cells. ***, pā€‰<ā€‰0.001

Back to article page